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Phorbol esters such as phorbol 12-myristate,l3_acetate (PMA) are potent activators of protein kinase C (PKC), and activate all PKC isozymes 
except c and A. Recently, 12-deoxyphorbol-13-O-phenylacetate-20-acetate (dPPA) and thymeleatoxin (TX) were reported to selectively activate 
PKC@, (dPPA) and PKCa, -B, and -y (TX), but not PKCS or PKCE in vitro. We examined the ability of these phorbol derivatives to translocate 
and down-regulate PKC isozymes in intact cells. Our findings demonstrate that dPPA and TX cause translocation and down-regulation of multiple 
PKC isozymes, including 6 and E. 
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1. INTRODUCTION 
Phosphorylation by protein kinase C (PKC) has an 
important role in signal transduction [l]. PKC modu- 
lates diverse cellular processes, such as secretion of 
hormones and neurotransmitters, gene expression, cell 
proliferation, and differentiation [2]. At least ten PKC 
isozymes have been identified, and can be divided into 
three, structurally related groups: conventional (cPKC; 
a, /Y,, b2 and y); novel (nPKC; 6, E, r]lL, and 0); and 
atypical (aPKC; g and a) [l]. cPKCs require phosphat- 
idylserine, Ca” and diacylglycerol for activation, 
whereas nPKCs are independent of Ca” and aPKCs 
require neither Ca2’ nor diacylglycerol. These isozymes 
exhibit subtle differences in substrate specificity and 
kinetic properties, and differ in their tissue distribution 
and subcellular localization [1,3,4]. Specific functions 
have been suggested for the different isozymes on the 
basis of their heterogeneous characteristics and distri- 
bution. However, relatively little is actually known 
about their individual roles, since no isozyme-selective 
activators or inhibitors are available. 
cPKC and nPKC isozymes respond to phorbol ester 
tumor promoters [l]. Phorbol esters mimic diacylglyc- 
erol and cause membrane association and activation of 
PKC [5,6]. Phorbol esters also increase the susceptibility 
of PKC to proteolytic degradation, and prolonged ex- 
posure to phorbol esters causes loss of PKC activity 
[7,8]. Thus, phorbol esters such as phorbol 12-myris- 
tate,l3-acetate (PMA) have been widely used as both 
acute activators and, with prolonged treatment, as in- 
hibitors of PKC. 
In addition to phorbol diesters, such as PMA, several 
chemically-related phorbol compounds have been iso- 
lated [9,10]. Major differences exist in the tumor-pro- 
moting capacity and other biological effects of these 
compounds [l l-l 31. Several bind and activate PKC 
with varying efficiency [14]. These compounds include 
12-deoxyphorbol-13-O-phenylacetate-20-acetate (dPPA) 
and a mezerein analog, thymeleatoxin (TX) [9,10]. Re- 
cently, Ryves et al. described selective activation of 
PKC/3, by dPPA and of PKCa, -/Jr and -y by TX, using 
an in vitro assay with purified PKC isozymes [15]. In 
this study, we investigated whether TX and dPPA selec- 
tively activate these PKC isozymes in intact cells by 
assaying their ability to stimulate PKC translocation 
from cytosol to particulate fractions. In addition, we 
treated cells with TX and dPPA for several hours to 
determine whether these agents could be used to selec- 
tively down-regulate specific PKC isozymes. 
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2. MATERIALS AND METHODS 
7116. 2.1. Materials 
PMA, TX and dPPA were obtained from LC Services Corp. 
Abbreviations: PMA, phorbol 12-myristate,l3_acetate; dPPA, 12-de- (Woburn, MA) and were stored at -20°C in dimethylsulfoxide at 
oxyphorbol-13-O-phenylacetate-20-acetate; TX, thymeleatoxin; PKC, lo-* M. Final dilutions were made immediately before use. Rabbit 
protein kinase C; PBS, phosphate-buffered saline. polyclonal anti-PKCd, -8, -E, and -5 were from Life Technologies 
Published by Elsevier Science Publishers B. V. 31 
Volume 3 19, number 1,2 FEBS LETTERS March 1993 
(Gaithersburg, MD) and mouse monoclonal anti-PKCB was from 
Seikagaku America (Rockville, MD). Peroxidase-conjugated anti-rab- 
bit and anti-mouse antibodies were from Boehringer Mannheim (Indi- 
anapolis. IN). Other chemicals were from Sigma (St. Louis, MO). 
Since dPPA can degrade in aqueous olutions, the stability of dPPA 
in culture medium was tested by thin-layer chromatography. dPPA 
was diluted to 100 PM In culture medium and was added to 35 mm 
culture dishes contaming 24 x lo6 PC12 cells per dish. After incuba- 
tion for 2224 h at 37”C, the medium was frozen, lyophilized, reconsti- 
tuted in ethyl acetate, and developed in hexane/ethyl acetate (1: 1) on 
fluorescent silica gel plates, Fresh dPPA was used as reference stand- 
ard. dPPA and degradation products were visualized under UV hght. 
2.2. PKC translocatzon 
PC12 cells were cultured in a humidified atmosphere of 10% CO, 
and 90% air in Dulbecco’s modified Eagle medium containing 10% 
heat-Inactivated horse serum, 5% fetal calf serum, 2 mM glutamine, 
50 U/ml penicillin and 50 @g/ml streptomycin. Cells were seeded into 
175 cm2 flasks (5-10 x lo6 cells/flask) and grown to 70-80% conflu- 
ence. Flasks were rinsed with buffer A containing 120 mM NaCI, 5 
mM KCl. 1.4 mM CaCI,, 0.8 mM MgSO,, 1 mM NaH,PO,, 10 mM 
glucose and 25 mM HEPES, pH 7.4. PMA, dPPA or TX were added 
at 100 nM in buffer A and cells were incubated at 37°C for 2 min. Cells 
were then dislodged from the flasks, centrifuged at 250 x g for 5 min. 
and resuspended in 2 ml of extraction buffer, containing 20 mM 
Tris-HCl (pH 7.5 at 4”C), 2 mM EDTA, 5 mM EGTA, 1 mM phen- 
ylmethylsulfonyl f uoride, 25 pg/ml of leupeptin and 25 pg/ml of soy- 
bean trypsin inhibitor. Cells were immediately homogenized with a 
Teflon-glass homogenizer, and centrifuged at 100,000 x g for 1 h at 
4°C. The supernatants were stored on ice and the pellets were resus- 
pended m 2 ml of extraction buffer containing 1% Triton X-100. The 
samples were mixed for 1 h at 4°C and centrifuged again at 100,000 x g 
for 1 h. Supernatants were diluted 4:l (v/v) with 5x sample buffer 
fix = 2% SDS, 10% glycerol, 0.025% Bromphenol blue. 62.5 mM 
Tns-HCl [pH 6.81). Samples were heated at 90°C for 5 min and equal 
volumes of membrane and cytosol fractions (60-95 pg) were separated 
on 9% acrylamide gels. 
2.3. Down-regulatron of PKC isoqmes 
Cells were treated with either dPPA (lo-1,000 nM) for 3 h. or TX 
(10-l ,000 nM) for 24 h. Cells were then collected in buffer A, centri- 
fuged at 250 xg for 5 min and resuspended in buffer A. Cells were 
centrifuged at 250 x g for 5 min and the pellet was resuspended at 3 
mg/ml in Ix sample buffer containing 1 mM phenylmethylsulfonyl 
fluoride, 25 &ml of leupeptin and 25 yg/ml of soybean trypsin inhib- 
itor. Samples were heated at 90°C for 5 min, and passed ten times each 
through a 21-gauge needle. After centrifugation at 10,000 x g for 10 
mm, 75 pg samples were subjected to SDS-PAGE on 9% acrylamide 
gels. 
2.4. Immunoblottrng 
Proteins were electrophoretically transferred from gels to nitrocellu- 
lose membranes [16]. Membranes were blocked in 2% bovine serum 
albumin in PBS for 1 h at room temperature, before mcubation with 
PKC isozyme-specific antibodies for 16-20 h at 4°C. Protein G-puri- 
fied rabbit polyclonal anti-PKCa, -6. -E, and -[ (0.5 mg/ml) were used 
at a dilution of 1:300 and mouse monoclonal anti-PKCB (100 .&ml) 
at 1:200. As demonstrated previously, these antibodies recognize pro- 
tems of appropriate molecular weight on Western blots, and im- 
munoreactivity against these bands is blocked by preincubation of 
each antibody with its corresponding PKC isozyme-specific antigen 
peptide or purified PKC isozyme [16]. Membranes were washed three 
times for 10 min in PBS/0.2% Tween-20 and then were incubated for 
1 h with peroxidase-conjugated anti-rabbit or anti-mouse antibodies 
(l:l,OOO dilution). Membranes were then washed four times m PBS/ 
0.2% Tween-20 and processed for detection of bands by chemilumines- 
cence with the ECL-chemiluminescence system (Amersham, Arlington 
Heights. IL) according to the manufacturer’s instructions. Blots were 
exposed to Kodak X-AR film and the autoradiograms were scanned 
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with a Microscan 1000 Gel Scanner (Technology Resources Inc.. 
Nashville, TN). Values were normalized against Coomassie stained 
gels as described [16]. Differences between mean density values from 
several experiments were compared by one way ANOVA and where 
significant differences were found (P < 0.05), the two-tailed Dunnett 
post-hoc test was used to identify significant differences between 
means of control and treated groups. 
3. RESULTS 
Nearly all PKCol and -j? immunoreactivity in unstim- 
ulated cells was found in the cytosol, whereas a consid- 
erable portion of PKCS, -E, and -6 immunoreactivity 
was localized in the particulate fraction (Figs. 1 and 2). 
As previously reported, no PKCy-immunoreactivity 
could be detected in our clone of PC12 cells [16]. The 
antibody to PKCE recognized a doublet of 90 and 92 
kDa (Figs. 1 and 3) as reported previously [16]. The 
different molecular masses of these two forms appear to 
be due to differences in phosphorylation [17]. Treat- 
ment of cells with 100 nM of either PMA, TX, or dPPA 
for 2 min resulted in a shift of PKCcr, -/I, -6 and -E 
immunoreactivity from the cytosol to the particulate 
fraction (Figs. 1 and 2), although translocation induced 
by PMA was greater than by dPPA or TX. The distribu- 
tion of PKCC between cytosol and particulate fractions 
was not affected by any of the phorbol derivatives. 
When stored in dilute solutions, dPPA may degrade 
to 12-deoxyphorbol 13-phenylacetate, which activates 
PKCa, -,B. -y, -6 and -E in vitro [15]. To investigate 
whether dPPA degrades in cultures of PC12 cells, we 
analyzed the stability of dPPA in media by thin-layer 
chromatography. dPPA added to cultures for 224 h 
remained intact (R, = 0.35-0.5), but after 12 h, another 
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Fig. 1 Translocation of PKC-isozymes by dPPA, TX, and PMA. Cells 
were treated with 100 nM dPPA. TX. or PMA for 2 min and fraction- 
ated into cytosol (C) and particulate (P) fractions. Samples of each 
fraction derived from equal numbers of cells were separated by SDS- 
PAGE, transferred to nitrocellulose and immunostained with antibod- 
ies against PKC isozymes. 
Control dPPA TX PMA 
InnI-t 
C PCPCPCP 
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spot (R, = 0.1-0.2) appeared, indicating degradation of 
dPPA. Therefore, we exposed cells to dPPA for only 3 
h to examine its ability to down-regulate PKC isozymes. 
dPPA (1 PM) almost completely eliminated PKCcc, #, 
-6 and -E immunoreacti~ty (Fig. 3). A lower concentra- 
tion (100 nM) caused partial down-regulation of PKC/I, 
-6 and -E immunoreactivity, but did not reduce levels of 
PKCa. Although 10 nM dPPA did not reduce PKC- 
immunoreactivity, it caused the appearance of a second 
species of PRCa, -@, -6 and -E with decreased mobility 
(Fig. 3). TX (100 nM-1 ,uM for 24 h) almost completely 
abolished PKCa, -@, -6 and -&-i~unorea~tivity, and 
a slight reduction was already detected with 10 nM TX 
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Ftg. 2. The percentage of total isozyme-specific immunoreactivity 
found in cytosol (open bars) and particulate (filled bars) fractions in 
control cells (con) and after treatment with 100 nM dPPA, TX or PMA 
for 2 min. Data are mean + S.E.M. values from 4-6 experiments. 
P = 0.0001 (alpha), 0.0001 (beta), 0.03 (delta), 0.0004 (epsilon), 0.762 
(zeta). * Significantly different from control (a = 0.05) by two-tailed 
Dunnett post-hoc test. 
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Fig. 3. Down-regulation of PKC by TX and dPPA. Cells were incu- 
bated with 10 nM-1 PM dPPA for 3 h or with 10 nM-1 PM TX for 
24 h and subjected to SDS-PACE, transferred to nitr~llulo~, and 
immunostained with isozyme-specific anti-PKC antibodies. Data are 
from a representative experiment repeated twice with similar results. 
c = control lane. 
(Fig. 3). PKCS-immunoreactivity was not affected by 10 
nM-1 PM dPPA or TX. 
4. DISCUSSION 
In order to study the role of different PKC isozymes 
in various physiological functions, it would be very use- 
ful to have selective activators and inhibitors of individ- 
ual PKC-isozymes or isozyme groups. In intact cells, 
activation of PKC isozymes is commonly assayed by 
measuring translocation of PKC activity and im- 
munoreactivity to particulate fractions [IS]. Transloca- 
tion is thought to reflect PKC activity, since it enables 
the interaction of PKC with membrane phospholipids, 
which all PKC subspecies appear to require for activa- 
tion [l]. The recent work of Ryves et al. [15] using an 
in vitro PKC assay suggested that dPPA might be used 
to selectively activate PKCF,, and TX to activate PKCa, 
-/I,, and -y in intact cells. However, we found that TX 
and dPPA induced translocation of all PKC isozymes 
except PKCC in PC12 cells. Thus, our results indicate 
that in intact cells, TX and dPPA induce translocation 
of several PKC isozymes and are, therefore, no more 
isozyme-selective than PMA. 
Our conclusions may contrast with those of Ryves et 
al. [15] because we used a translocation assay to meas- 
ure PKC activation. Although association of PKC 
isozymes with lipid-containing particulate fractions is 
thought to be necessary for activation 1191 membrane 
binding of PKC may occur without activation. For ex- 
ample, in inside-out erythrocyte vesicles, membrane 
binding of PKC is maximal at 500 nM Ca2’, whereas 
PKC is activated by 5-50 PM Ca*+ when diacylglycerol 
33 
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or phorbol esters are absent [19]. Moreover, in vitro, 
PKC activity is inhibited by salt concentrations that fail 
to dissociate PKC from lipid vesicles [20]. In addition, 
staurosporine causes PKC translocation but inhibits 
PKC activation 1211. However, we are unaware of any 
studies demonstrating PKC translocation without acti- 
vation in intact cells in the absence of PKC inhibitors. 
On the other hand, PKC activation may occur without 
translocation [22,23], suggesting that, in some cases, 
translocation is an insensitive indicator of activation. In 
such cases, the inability to detect significant transloca- 
tion might be due to activation of nPKCs, since a major 
fraction of nPKCs, especially 6, is already present in the 
particulate fraction of unstimulated cells (Figs. 1 and 2, 
and [24-271). Despite the relative insensitivity of the 
translocation assay, we were able to detect ranslocation 
of nPKCs after treatment with dPPA and TX. Thus, our 
results strongly suggest that dPPA and TX activate 
nPKCs in intact cells. 
Our results also demonstrate that dPPA and TX can 
not be used to selectively down-regulate cPKCs. The 
down-regulation of multiple PKC-isozymes by TX and 
dPPA, as well as the appearance of isozyme subspecies 
with decreased mobility on SDS-acrylamide gels after 
treatment with dPPA (Fig. 3) demonstrates that these 
phorbol derivatives, like PMA, have major effects on 
multiple PKC isozymes after prolonged exposure. 
Taken together with the findings of our translocation 
studies, these results indicate that dPPA and TX regulate 
multiple cPKC and nPKC isozymes in intact cells, and 
are no more isozyme-selective than PMA for studies of 
PKC translocation or down-regulation. 
Acknowledgements: This work was supported by grants from the Na- 
tional Institute on Alcohol Abuse and Alcoholism and a grant from 
the Alcoholic Beverage Medical Research Foundation to R.O.M. 
REFERENCES 
[l] Nishizuka, Y. (1992) Science 258, 607-614. 
[2] Nishizuka, Y. (1986) Science 233, 305-312. 
[3] Nishizuka, Y. (1988) Nature 334, 661-665. 
L41 
[51 
El 
[71 
PI 
[91 
UOI 
Ufl 
WI 
u31 
[I41 
1151 
[I61 
t171 
1181 
u91 
CN 
VI 
[221 
~31 
v41 
~51 
WI 
~71 
Wetsel, W.C., Khan, W.A., Merchenthaler, I., Rivera, H., Halp- 
ern. A.E., Phung, H.M., Negro-Vilar, A. and Hannun, Y.A. 
(1992) J. Cell Biol. 117, 121-133. 
Kraft, AS. and Anderson, W.B. (1983) Nature 301, 621-623. 
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U. 
and Nishizuka, Y. (1982) J. Biol. Chem. 257, 784777851. 
Young, S., Parker, P.J., Ullrich, A. and Stabel, S. (1987) BIO- 
them. J. 244, 775-779. 
Chida, K., Kato, N. and Kuroki, T. (1986) J. Biol. Chem. 261, 
13013-13018. 
Hergenhahn, M., Kusumoto, S. and Becker, E. (1974) Experien- 
tia 30, 1438-1440. 
Rizk, A.M., Hammouda, F.M., Ismail, S.E., El-Missiry, M.M. 
and Evans, F.J. (1984) Experientia 40, 808-809. 
Brooks, G., Evans, A.T., Aitken, A. and Evans, F.J. (1989) 
Carcinogenesis 10, 283-288. 
Driedger, P.E. and Blumberg, P.M. (1979) Cancer Res. 39, 714 
719. 
Driedger, P.E. and Blumberg, P.M. (1980) Cancer Res 40, 339- 
346. 
Ellis, C.A., Brooks, S.F.. Brooks, G.. Evans, A.T., Morrice, N., 
Evans, F.J. and Aitken, A. (1987) Phytother. Res. I, 187-190. 
Ryves, W.J., Evans, A.T., Olivier, A.R., Parker. P.J. and Evans, 
F.J. (1991) FEBS Lett. 288, 559. 
Messing, R.O., Petersen, P.J. and Henrich, C.J. (1991) J. Biol. 
Chem. 266, 23428-23432. 
Koide, H., Ogita, K., Kikkawa, U. and Nishizuka, Y. (1992) 
Proc. Natl. Acad. Sci. USA 89, 1149-l 153. 
Woodget, J.R., Hunter, T. and Gould, K.L. (1987) in: Cell Mem- 
branes: Methods and Reviews (E. Elson, W. Frazier and L. 
Glaser, eds.), Plenum Press, New York, pp. 215-340. 
Wolf, M., Levine III, H., May Jr., W.S., Cuatrecasas, P. and 
Sahyoun, N. (1985) Nature 317, 546549. 
Bazzi, M.D. and Nelsestuen, G.L. (1987) Biochemistry 26. 1974 
1982. 
Wolf, M. and Baggiolini, M. (1988) Biochem. Biophys. Res. 
Commun. 154, 1273-1279. 
Wolf, B.A., Williamson, J.R., Easom. R.A.. Chang, K., Sherman, 
W.R. and Turk, J. (1991) J. Clin. Invest. 87. 31-38. 
Trilivas, I., McDonough. P.M. and Brown, J.H. (1991) J. Biol. 
Chem. 266, 8431-8438. 
Akita, Y., Ohno, S., Konno, Y., Yano, A. and Suzuki, K. (1990) 
J. Biol. Chem. 265, 354-362. 
Mizuno, K., Kubo, K., Saido, T.C., Akita, Y.. Osada, S., Kuroki, 
T., Ohno, S. and Suzuki, K. (1991) Eur. J. B&hem. 202,931-940. 
Ogita, K., Shin-ichi, M., Yanaguchi, K., Koide, H., Fujisawa, N., 
Kikkawa, U., Sahara, S., Fukami, Y. and Nishizuka, Y. (1992) 
Proc. Natl. Acad. Sci. USA 89, 1592-1596. 
Osada, S.-I., Mizuno. K., Saido, T.C., Suzuki, K., Kuroki, T. and 
Ohno, S. (1992) Mol. Cell. Biol. 12, 3930-3938. 
34 
